Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  Celltrion, Inc.    068270   KR7068270008

CELLTRION, INC. (068270)
Mes dernières consult.
Most popular
  Report  
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (KRW)
Sales 2018 1 220 B
EBIT 2018 651 B
Net income 2018 501 B
Finance 2018 124 B
Yield 2018 -
Sales 2019 1 625 B
EBIT 2019 914 B
Net income 2019 705 B
Finance 2019 457 B
Yield 2019 -
P/E ratio 2018 67,47
P/E ratio 2019 48,20
EV / Sales2018 27,5x
EV / Sales2019 20,4x
Capitalization 33 654 B
More Financials
Company
Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals.It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses.Its products include remsima and biosimilars.The company was founded on February 27, 1991 and is headquartered in Incheon,... 
More about the company
Surperformance© ratings of Celltrion, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on CELLTRION, INC.
04/21CELLTRION : s Truxima approved in Australia
AQ
04/08TEVA PHARMACEUTICAL INDUSTRIES : faces delay in biosimilars launch
AQ
04/07CELLTRION : FDA rejects Teva/Celltrion biosimilars
AQ
04/07TEVA PHARMACEUTICAL INDUSTRIES : Plant issues plague Celltrion and Teva as FDA i..
AQ
04/06Interbrand announces Best Korea Brands 2018
AQ
04/06TEVA PHARMACEUTICAL INDUSTRIES : US FDA rejects Teva biosimilars made at trouble..
AQ
03/24CELLTRION : to complete final clinical trials of Remsima SC by Sept.
AQ
03/21Britain's use of copycat biotech drugs takes off while U.S. lags
RE
03/17CELLTRION`S MANUFACTURING HEADACHE L : analysts
AQ
03/09BIOCENTURY - MANAGEMENT TRACKS : Takeda, Nimbus
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Biotechnology & Medical Research - NEC
Chart CELLTRION, INC.
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | 068270 | KR7068270008 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 237 099  KRW
Spread / Average Target -12%
EPS Revisions
Managers
NameTitle
Wu-Sung Ki Co-Chief Executive Officer & Director
Hyung-Ki Kim Co-Chief Executive Officer & Director
Jung-Jin Seo Director
Dong-Il Kim Outside Director
Joseph Lee Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.31 467
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258
LONZA GROUP-6.95%18 703
INCYTE CORPORATION-27.75%14 493
NEKTAR THERAPEUTICS44.36%13 873